

Important Prescribing Information

November 5, 2024

Subject: Temporary importation of Plasma-Lyte 148 (pH 7.4) Solution for Infusion from Sabiñánigo, Spain to address drug shortages

Dear Healthcare Professional,

To prevent a drug shortage of large volume parenteral fluid drug products, Baxter Healthcare Corporation (Baxter) is coordinating with the U.S. Food and Drug Administration (FDA) to temporarily import Plasma-Lyte 148 (pH 7.4) Solution for Infusion (1,000 mL) from Baxter's manufacturing facility in Sabiñánigo, Spain. FDA has not approved this product manufactured by Baxter's Sabiñánigo facility.

You may be provided with additional letters for other imported products you receive. Please read each letter in its entirety because each letter may contain different, product-specific information.

At this time, no other entity except Baxter is authorized by the FDA to import or distribute this imported product in the United States.

Effective immediately, and during this temporary period, Baxter will offer the following imported product:

Product name and description	Size	Product code	Bags per carton	NDC code of a single bag
Plasma-Lyte 148 (pH 7.4) Solution for Infusion	1,000 mL	GCCE0324	10	0338-9593-01

It is important to note the following:

- After opening the carton or box, the bags should be inspected visually to confirm there is no visible
 particulate matter or bag defects, such as leaks. Container integrity is imperative to ensure sterility of the
 products listed in the table above. Parenteral drug products should be inspected visually for particulate
 matter and bag defects prior to administration, whenever solution or container permits.
 USE A NEW BAG IF PARTICULATES ARE VISIBLE OR IF THE IV BAG CONTAINS A LEAK.
- The imported product's administration port system is fully compatible with Baxter sets marketed in the United States.

- The imported product does not contain a barcode on the unit label. Institutions should manually input the product into their systems and take appropriate precautions to ensure accurate product identification in processes and workflows. Alternative procedures should be followed to ensure that the correct drug product and concentration is being used in all systems and processes and administered to individual patients. A barcode containing the NDC number for the imported product will be made available online.
- Plasma-Lyte A Injection pH 7.4 is available only by prescription in the United States. However, the imported product does not have the statement "Rx only" on the labeling.

Additional key differences in the labeling between the FDA-approved product and the imported product are stated in the product comparison tables at the end of this letter as follows:

Table 1 Key differences in FDA-approved Plasma-Lyte A Injection pH 7.4 and imported Plasma-Lyte 148 (pH 7.4) Solution for Infusion

Table 2 Label images of FDA-approved Plasma-Lyte A pH 7.4 and imported Plasma-Lyte 148 (pH 7.4) Solution for Infusion

Please refer to the FDA-approved prescribing information for the drug product listed below:

Plasma-Lyte A Injection pH 7.4 (click <u>here</u>)

Reporting Adverse Events or Product Quality Issues

To report **adverse events** associated with this imported product, please call Baxter at 1-866-888-2472, or fax: 1-800-759-1801. Adverse events or quality problems experienced with the use of this imported product may also be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax:

- Complete and submit the report **Online**: www.fda.gov/medwatch/report.htm
- Regular mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178 (1-800-332-0178).

To report **product quality issues** associated with this imported product, please contact Baxter Product Surveillance through Baxter Product Feedback Portal (https://productfeedback.baxter.com/).

If you have any questions about the information contained in this letter or the use of the imported product, please contact Baxter's Medical Information Service at 1-800-933-0303.

Sincerely,
Electronically signed by: Lee
Electronically signed by: Lee Ann Schuette Reason: I approve this Lee Ann Schuett Biocument Date: Nov 5, 2024 11:17 CST
Lee Ann Schuette
VP Global and US Marketing IV solutions, Clinical Nutrition, Pharmacy Tools
Baxter Healthcare Corporation
Baxter, Viaflo, and Viaflex are trademarks of Baxter International Inc.

To place an order, please contact Baxter's Center for Service by calling 1-888-229-0001.

Table 1 Key differences in FDA-approved Plasma-Lyte A Injection pH 7.4 and imported Plasma-Lyte 148 (pH 7.4) Solution for Infusion

	FDA-approved product			Imported product from Spain				
Product name	Plasma-Lyte A Injection pH 7.4 (Multiple Electrolytes Injection Type 1 USP)			Plasma-Lyte 148 (pH 7.4) Solution for Infusion				
Label Volume	1,000 mL				1,000 mL			
Indications	PLASMA-LYTE A Injection pH 7.4 (Multiple Electrolytes Injection, Type 1, USP) is indicated as a source of water and electrolytes or as an alkalinizing agent.		, Plasma-Lyte 148	Plasma-Lyte 148 (pH 7.4) is indicated:				
			- for fluid replacement (e.g. after burns, head injury, fracture, infection, and peritoneal irritation),					
				- as intraoperativ	- as intraoperative fluid replacement,			
				- in haemorrhagic shock and clinical conditions requiring rapid blood transfusions (compatibility with blood),				
		- in mild to moderate metabolic acidosis, also in case of lactate metabolism impairment.			ase of lactate			
Active		Each :	100 mL contains			Each 10	0 mL contains	
Ingredients	526 mg		m Chloride		526 mg	•	um Chloride	
	502 mg Sodium Gluconate			502 mg		um Gluconate		
	368 mg Sodium Acetate Trihydrate		368 mg		um Acetate Trihydra	ate		
	37 mg		sium Chloride	avdrata	37 mg Potassium Chloride 30 mg Magnesium Chloride Hexahydrate			vahvdrata
	30 mg	iviagn	esium Chloride Hexal	iyurate	30 mg	iviag	nesium Chioride He	xanyurate
Additional	pH 6.5 - 8.0			Hq	1 6.5 - 8.0			
information	Osmolarity 294 mOsmol/L (calc)			Os	•	5 mOsmol/L (approx	r)	
	mEq/L		mEq/L					
	Sodium	140	Chloride	98	Sodium	140	Chloride	98
	Potassium	5	Acetate	27	Potassium	5	Acetate	27
	Magnesium	3	Gluconate	23	Magnesium	3	Gluconate	23
Storage Conditions	Store at room temperature 25°C/77°F				Store be	low 30°C/86°F		
Container type	VIAFLEX (PVC)				VIAFL	.O (nonPVC)		

SI-ITT-SAB-DHCP-202411-01, Rev 00 Page 4 of 6

	FDA-approved product	Imported product from Spain
Medication and Administration port closures	Contains medication port and administration port; Pull off port protector (blue color)	Contains medication port and administration port; Twist off port protector (natural color)

SI-ITT-SAB-DHCP-202411-01, Rev 00 Page 5 of 6

Table 2 Label images of FDA-approved Plasma-Lyte A pH 7.4 and imported Plasma-Lyte 148 (pH 7.4) Solution for Infusion

FDA-approved product	-	Imported product from Spain
Plasma-Lyte A Injection pH 7.4		Plasma-Lyte 148 (pH 7.4)
(Multiple Electrolytes Injection Type 1 USP)		Solution for Infusion
Label Color: Black.		Label Color: Black.
Barcode, lot number, and expiry are not shown	l .	Lot number and expiration date are not shown.
Barcode, lot number, and expiry are not shown LOT EXP O O 282544 Plasma-Lyte A Injection pH 7.4 (Multiple Electrolytes Injection Type 1 USP) 1000 mL EACH 100 mL CONTAINS 528 mg SCOUN CALORIDE USP 502 mg Scoul Gluconate USP 388 mg Scoul Active USP 502 mg Scoul Gluconate USP 388 mg Scoul Active USP 502 mg Scoul Gluconate USP 388 mg Scoul Active USP 30 mg MAGNESIUM CHLORIDE USP 38 mg Scoul Active USP 30 mg MAGNESIUM CHLORIDE USP pH ADJUSTED WITH SCOULUM HYDROXIDE PH 7.4 (6.5 to 8.0) mEq/L Scoul 140 Potassium 5 MAGNESIUM 3 CHLORIDE USP ACETATE 27 GLUCONATE 23 CANOLARTY 204 mOsmol/L (CALC) STEPLE NORMYROGENIC SINGLE DOSE CONTAINER ADDITIVES MAY BE NOCEMBATRICE CONSULT WITH PHARMANICIST IF MALLAGE. WHEN INTRODUCING ACCUTIVES USE ASSIPTIC TECHNOLOGY MX THOROLOGIUS WITH INTRODUCING ACCUTIVES USE ASSIPTIC TECHNOLOGY WITH INTRODUCING ACCUTIVES USE ASSIPTIC TECHNOLOGY MX THOROLOGY WITH INTRODUCING ACCUTIVES USE ASSIPTIC TECHNOLOGY WITH ACCUT	1 2 3 4 5	Baxter GCCE0324 1000 mL 100 Plasma-Lyte 148 (pH 7.4) 300 Solution for Infusion pH 6.5 – 8.0 Isotonic Osmolarity 295 m0sm/l (approx) Formula per 1000 mL Sodium Chloride 0.37 g Potassium Chloride hexahydrate 0.30 g Sodium Acetate trihydrate 3.68 g Sodium Gluconate 5.02 g Water for Injections Sodium Hydroxide mmol per 1000 mL (approx) Sodium 140 Chloride 98 700 Potassium 5 Acetate 27 Magnesium 1.5 Gluconate 23
DO NOT STORE DOSAGE INTRAVENCUSLY AS DIRECTED BY A PHYSICIAN SEE DIRECTIONS CAUTIONS SOLICES AND RISPECT INNER BAG WHICH MAINTAINS PRODUCT STERRITY DISCARD IF LEASS ARE FOUND MUST NOT BE USED IN SERIES CONNECTIONS DO NOT USE UNLESS SOLUTION IS CLEAR RX ONLY STORE UNIT IN MOISTURE BARRIER OVERWAAP AT ROOM TEMPERATURE (25°C?77°F) UNTIL READY TO USE AVOID EXCESSIVE HEAT SEE HIGHT VIAFLEX CONTAINER PL 146 PLASTIC BAXTER PLASMA-LYTE VIAFLEX AND PL 146 ARE TRADEMARKS OF BAXTER INTERNATIONAL INC FOR PRODUCT INFORMATION 1-800-833-0303	6 7 8	IV administration Read package leaflet before use Keep out of the sight and reach of children Do not remove from overwrap until ready for use Do not use unless solution is clear without visible particles and container undamaged Do not reconnect partially used bags Store below 30°C POM 900
BAXTER HEALTHCARE CORPORATION DEEPFELD IL 60015 USA MADE IN USA	_	Marketing Authorisation Holder: Baxter Healthcare Ltd. Caxton Way Thetford Morfolk IP24 3SE United Kingdom UN-35-03-560 Manufacturer: Bieffe Medital S.A. Ctra de Biescas-Senegüé 22666 Sabiñánigo (Huesca) Spain
	9	LOT EXP

SI-ITT-SAB-DHCP-202411-01, Rev 00 Page 6 of 6